Virology Resource Core

JH-EPICS病毒学资源核心(VRC)摘要 约翰·霍普金斯SARS-CoV-2致病和免疫卓越中心(JH-EPICS)旨在 系统分析先天、T细胞和抗体的反应，保护或引起病理过程 SARS-CoV-2感染。为了准确地完成三部JH史诗中的具体目标 在研究项目中，需要一致和可靠的病毒特异性试剂和方法来源。这个 病毒学资源核心(VRC)的任务是提供SARS-CoV-2特异性试剂和访问BSL3 三个JH-EPICS研究项目的病毒感染细胞实验设施。VRC 利用Andrew Pekosz博士(牵头)和Michael Betenbaugh博士(联合牵头)的专业知识来生成 这些试剂。Vrc将产生重组蛋白质，特别是具有复合体的蛋白质。 碳水化合物的部分。VRC有能力利用哺乳动物细胞表达少量或大量的 所有JH-EPICS研究项目将使用的纯化蛋白来测量病毒抗原特异性 回应。VRC的领导有处理呼吸道病毒的经验，如流感、SARS-CoV和 SARS-CoV-2，这将使VRC严格和准确地生长并提供JH-EPICS 具有一致来源的病毒颗粒或已灭活的受感染细胞裂解物的研究项目 并可用于BSL3-安全壳以外的实验室。VRC将提供专业知识和访问 在感染病毒的细胞上进行实验所需的设施，这将使JH-EPICS 调查人员用活病毒验证结果。这些试剂的集中生产，使用 病毒感染的标准化方案，以及在JH-EPICS研究项目中的一致使用将 提高数据的质量、严密性和重复性，以增加JH-EPICS的公共卫生意义 学习。

JH-EPICS Virology Resource Core (VRC) Summary The Johns Hopkins Excellence in Pathogenesis and Immunity Center for SARS-CoV-2 (JH-EPICS) aims to systematically analyze the innate, T cell, and antibody responses that either protect or cause pathology during SARS-CoV-2 infection. In order to accurately accomplish the Specific Aims within the three JH-EPICS Research Projects, a consistent and reliable source of virus-specific reagents and methods is required. The Virology Resource Core (VRC) is tasked with providing SARS-CoV-2-specific reagents and access to BSL3 facilities to perform experiments with virus infected cells for the three JH-EPICS Research Projects. The VRC draws on the expertise of Andrew Pekosz, PhD (Lead) and Michael Betenbaugh, PhD (Co-Lead) to generate these reagents. The VRC will produce recombinant proteins and, in particular, proteins with complex carbohydrate moieties. The VRC has the ability to use mammalian cells to express small or large quantities of purified proteins that will be used by all the JH-EPICS Research Projects to measure viral antigen specific responses. The Lead of the VRC has experience with respiratory viruses, such as influenza, SARS-CoV, and SARS-CoV-2, which will enable the VRC to rigorously and accurately grow and provide the JH-EPICS Research Projects with a consistent source of virus particles or infected cell lysates that have been inactivated and can be used in laboratories outside of BSL3-containment. The VRC will provide the expertise and access to facilities necessary to perform experiments on virus-infected cells, which will allow the JH-EPICS investigators to validate results with live virus. The centralized production of these reagents, the use of standardized protocols for virus infections, and consistent use across JH-EPICS Research Projects will improve the quality, rigor, and reproducibility of data to increase the public health significance of the JH-EPICS studies.